Mechanism of action of nusinersen | Download Scientific Diagram
Frontiers | Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment | Pharmacology
Small molecule recognition of disease-relevant RNA structures - Chemical Society Reviews (RSC Publishing) DOI:10.1039/D0CS00560F
Risdiplam: Editing on the RNA level – a dream or a nightmare? – Spinal Muscular Atrophy as example
Mechanism of Action of Risdiplam | CheckRare
Comparative evaluation of AAV gene therapy, antisense therapy and small molecules therapy for treatment of SMA for efficacy and
RNA in spinal muscular atrophy: therapeutic implications of targeting
New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges
Risdiplam, the First Approved Small Molecule Splicing Modifier Drug as a Blueprint for Future Transformative Medicines
RNA-Targeted Therapies and High-Throughput Screening Methods
The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscula
Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care. - Abstract - Europe PMC
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscula
Targeting the 5′ untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy: Molecular Therapy - Nucleic Acids
Risdiplam - Wikipedia
Gene specific therapies – the next therapeutic milestone in neurology | SpringerLink
Document
Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers. - Abstract - Europe PMC
Risdiplam: Editing on the RNA level – a dream or a nightmare? – Spinal Muscular Atrophy as example
IJMS | Free Full-Text | New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand? | HTML
Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy | Scientific Reports
Evrysdi (risdiplam) for the Treatment of Spinal Muscular Atrophy (SMA)
Combined treatment with the histone deacetylase inhibitor LBH589 and a splice‐switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells - Pagliarini - 2020 - Journal of Neurochemistry -
Risdiplam | C22H23N7O - PubChem
